Coeptis Therapeutics Expands License Agreement with Deverra
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) recently announced an important expansion of its license agreement with Deverra Therapeutics Inc. This move significantly broadens the potential of its innovative allogeneic natural killer (NK) cell technology, now including unmodified NK cells aimed at addressing viral infections, pandemic-related illnesses, and emergency preparedness for future health crises.
Enhancing Pandemic Preparedness
This updated agreement permits the use of NK cells in emergency situations, reacting promptly to health threats such as pandemics or acts of terror. David Mehalick, the President and CEO of Coeptis Therapeutics, expressed enthusiasm about this broadening scope. "We are delighted to expand our field of use to now include pandemic and emergency situations, as it now broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic," he stated.
License Agreement Details
In mid-2023, Coeptis secured an exclusive license from Deverra that includes valuable resources such as an allogeneic stem cell expansion and directed differentiation platform. Additionally, they acquired two investigational new drug applications and two clinical-stage assets specifically focusing on DVX201 as an unmodified NK cell therapy. This initiative aligns with Coeptis’ overall mission to develop advanced treatments targeting various diseases, including cancer and autoimmune disorders.
Key Areas of Expansion
The revised license agreement focuses on two significant areas: pandemic-related and emergency preparedness, which allows for the production and stockpiling of unmodified NK cells before health crises occur.
Future Prospects for Coeptis Therapeutics
With a strong commitment to advancing cell therapy technologies, Coeptis is poised to potentially disrupt traditional treatment methods that currently exist for autoimmune and infectious diseases. Its ongoing research into NK cell therapies could transform patient care by providing more effective alternatives.
The Mission of Coeptis Therapeutics
Coeptis Therapeutics, together with its subsidiaries, is dedicated to developing cutting-edge cell therapies. Their aim is to improve patient outcomes and transform the treatment landscape for cancers and infectious diseases. Coeptis holds significant assets from Deverra Therapeutics and is also innovating in areas like CAR T technology licensed from the University of Pittsburgh.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc. focuses on developing groundbreaking therapies using cell technology. The company’s portfolio features assets designed to address unmet medical needs, particularly in the realms of cancer and infectious diseases. Coeptis has established a robust business model aiming to expand its therapeutic offerings through strategic partnerships and innovative research.
Frequently Asked Questions
1. What is the recent announcement made by Coeptis Therapeutics?
Coeptis Therapeutics has expanded its license agreement with Deverra to enhance their NK cell therapy for pandemic preparedness and emergency situations.
2. What is NK cell therapy?
NK cell therapy utilizes natural killer cells to attack infected or malignant cells, representing a promising approach to treating various diseases.
3. How does this agreement affect pandemic preparedness?
The agreement allows the production and storage of NK cells in advance of potential health crises, enabling a quicker response to emergencies.
4. What are some key assets included in the license?
The license includes an allogeneic stem cell expansion platform, IND applications, and assets for clinical trial investigations of NK cell therapy.
5. How does Coeptis Therapeutics plan to improve patient outcomes?
Coeptis aims to innovate and expand its cell therapy technologies, enhancing treatment options for cancer and infectious diseases while maximizing patient outcomes.
